Study of guselkumab for psoriatic arthritis in Indian patients
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with active psoriatic arthritis (PsA) by a doctor using specific criteria.
- Your arthritis has not responded well to standard treatments like methotrexate or NSAIDs after trying them for at least 3 months.
- You have never taken biological drugs for PsA, or you have tried one or two (like anti-TNF or IL-17 inhibitors) and they didn't work or caused side effects.
- You do not have active or untreated tuberculosis (TB), and you are willing to undergo TB testing before starting the study.
- You are not pregnant or planning to become pregnant, and if you are a woman of childbearing potential, you must have a negative pregnancy test.
- You have no history of serious infections, cancer, or recent live vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing how well guselkumab works for people with psoriatic arthritis who are starting it in everyday medical practice. Researchers want to see if the drug helps reduce joint swelling and tenderness, and if it can improve enthesitis (pain where tendons attach to bone).
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
This study tests if guselkumab can reduce pain and inflammation in people with psoriatic arthritis. You may join if standard treatments have not worked well enough or caused side effects.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
Hear when a new Arthritis, Psoriatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.